CTOs on the Move

Robert Half

www.roberthalf.com

 
Robert Half, the world`s first and largest specialized talent solutions firm, connects opportunities at great companies with highly skilled job seekers. We offer contract, temporary and permanent placement solutions for roles in finance and accounting, technology, marketing and creative, legal, and administrative and customer support. Named to Fortune`s World`s Most Admired Companies and 100 Best Companies to Work For® lists and a Forbes Best Employer for Diversity, Robert Half is the parent company of Protiviti®. Robert Half is traded on the New York Stock Exchange (symbol: RHI) and is a member of the S&P 500 index.
  • Number of Employees: 250-1000
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Sara Gagen
Senior Vice President of Applications, Technology and Innovation Profile
Ryan Sutton
Executive Director of Technology Practice Profile
James Johnson
Executive Vice President and Chief Technology Officer Profile
Jake Wojtowicz
Division Director at Robert Half Technology Profile
Clint Maples
Chief Information Security Officer Profile

Jobs

CTO - Chief Technology Officer

Robert Half Florham Park, NJ
Description :
We are currently recruiting for a full time CHIEF SECURITY OFFICER for a client in Morris County, NJ to be responsible for the conception, development, implementation, and management of the corporate security strategy.

Providing strategic leadership and direction for the organization’s information and security function and coordinate ...

Similar Companies

Dental Technologies

Dental Technologies, Inc is a company specializing in the research, formulation, compounding and packaging of dental, orthodontic and oral pharmaceutical products.

New Mexico Health Connections

New Mexico Health Connections will be a consumer-oriented and operated health plan, governed by experts in health care, consumer protection and medicine.

Belmont Manor Nursing Home Inc

Belmont Manor Nursing Home Inc is a Belmont, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LearnWright

LearnWright is a Potomac, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eleven Biotherapeutics

"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."